Cano Health Announces Financial Results for the Fourth Quarter and Full Year 2022
Cano Health reported significant financial results for Q4 and full year 2022, marking total revenue of $680.4 million in Q4, up 38% year-over-year, and $2.74 billion for the full year, representing a 70% increase.
Despite the revenue growth, Cano Health faced a net loss of $301.7 million in Q4, influenced by a $323 million non-cash goodwill impairment. Adjusted EBITDA improved to $35.7 million in Q4 from $11.1 million previously.
The company anticipates a membership increase to 375,000-385,000 and revenue guidance of $3.10-$3.25 billion for 2023 while adjusting its medical cost ratio expectations to 81%-82%.
- Total revenue increased by 38% to $680.4 million in Q4 2022.
- Total revenue for 2022 reached $2.74 billion, a 70% increase year-over-year.
- Adjusted EBITDA improved to $35.7 million in Q4 2022, up from $11.1 million the prior year.
- Membership grew to 309,590, with a 42% increase in Medicare capitated members.
- Net loss for Q4 2022 was $301.7 million, largely due to a $323 million non-cash goodwill impairment.
- Net loss for the full year 2022 totaled $428.4 million.
- Adjusted EBITDA for 2022 would have been approximately $74 million under new metrics, indicating operational challenges.
MIAMI, March 1, 2023 /PRNewswire/ -- Cano Health, Inc. ("Cano Health" or the "Company") (NYSE: CANO), a leading value-based primary care provider and population health company, today announced financial results for the fourth quarter and full year ended December 31, 2022.
Fourth Quarter 2022 Financial Results
- Total membership of 309,590 including 179,536 Medicare capitated members, an increase of
36% and42% year-over-year, respectively - Total revenue of
$680.4 million , compared to$492.3 million the prior year, an increase of38% year-over-year - Net loss of
$(301.7) million , unfavorably impacted by a non-cash goodwill impairment of$(323.0) million , partially offset by a gain of$81.2 million due to a fair value adjustment of warrant liabilities - Adjusted EBITDA[1] of
$35.7 million , compared to$11.1 million in the prior year
Full Year 2022 Financial Results
- Total revenue of
$2,738.9 million , compared to$1,609.4 million in the prior year, an increase of70% year-over-year - Net loss of
$(428.4) million , inclusive of the previously mentioned non-cash goodwill impairment of$(323.0) million - Adjusted EBITDA of
$152.5 million , compared to$27.3 million in the prior year
In the fourth quarter of 2022, capitated revenue of
"At Cano Health, we are determined to achieve our vision by helping our patients live their best lives," said Dr. Marlow Hernandez, Chairman and Chief Executive Officer at Cano Health. "We completed 2022 with membership well above our initial expectations, and revenue and Adjusted EBITDA in line with our most recent guidance. In 2023, we will focus on optimizing our operations to unlock embedded profitability at our existing medical centers by utilizing available capacity. Moreover, we are committed to reviewing all aspects of our value-based platform to improve liquidity and cash flow, and maximize long-term shareholder value."
_____________________________________ |
1 Adjusted EBITDA is a non-GAAP financial measure defined under the heading "Non-GAAP Financial Measures". A reconciliation of this non-GAAP financial measure to its most directly comparable GAAP financial measure is provided in the Reconciliation of Non-GAAP Adjusted EBITDA table included in this press release. |
2 Medical Cost Ratio (MCR) is calculated as third-party medical expense divided by capitated revenue. |
Capital Management Update
On February 24, 2023, the Company consummated the closing of a
The 2023 Term Loan bears interest at
In connection with the 2023 Term Loan, the Company issued to the investors warrants to purchase up to approximately 29.5 million shares of the Company's Class A common stock, or up to
2023 Guidance
The Company provided its full year 2023 guidance, as detailed below:
- Membership by year-end in the range of 375,000 to 385,000
- Total revenue in the range of
$3.10 billion to$3.25 billion - Total medical cost ratio (MCR) in the range of
81.0% to82.0% - Adjusted EBITDA of approximately
$75 million to$85 million , excluding de novo loss add-backs - The Company plans to significantly reduce de novo investments in 2023; therefore, beginning with 2023, the Company is revising its definition of Adjusted EBITDA to no longer add back de novo losses, which include those costs associated with the ramp up of new medical centers and losses incurred up to 12 months after the opening of a new facility
- Under the new definition, Adjusted EBITDA would have been approximately
$74 million for the full year 2022
As of February 24, 2023, the Company had approximately 239 million shares of Class A common stock and 267 million shares of Class B common stock issued and outstanding. Total share count for the purposes of calculating the Company's market capitalization was approximately 507 million.
Conference Call Information
Cano Health will host a conference call today at 5:00 PM ET to review the Company's business and financial results for the fourth quarter and full year ended December 31, 2022.
To access the live call and webcast, please dial (888) 660-6359 for U.S. participants, or +1 (929) 203-0867 for international participants, and reference the Cano Health Fourth Quarter 2022 Earnings Conference Call and Conference ID 8371699. The conference call will also be webcast live in the "Events & Presentations" section of the Investor page of the Cano Health website.
A replay will be available in the "Events & Presentations" section of the Cano Health website for on-demand listening shortly after the completion of the call and will be available for 30 days.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements relate to future events and involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and could materially affect actual results, performance or achievements. Such forward-looking statement include, without limitation, our anticipated results of operations, including our financial guidance for the 2022 fiscal year, our business strategies, our projected costs, prospects and plans, and other aspects of our operations or operating results. These forward-looking statements generally can be identified by phrases such as "will," "expects," "anticipates," "foresees," "forecasts," "estimates" or other words or phrases of similar import, including, without limitation, the Company's (i) plans to achieve our vision by helping our patients live their best lives; (ii) plans to focus in 2023 on optimizing our operations to unlock embedded profitability at our existing medical centers by utilizing available capacity; (iii) plans and expectations with respect to reviewing all aspects of our value-based platform to improve liquidity and cash flow, and maximize long-term shareholder value, including our plans to significantly reduce de novo investments in 2023; (iv) intent to use proceeds from the 2023 Term Loan transaction for general corporate purposes, including repaying amounts outstanding under our existing revolving credit facility, and to pay transaction fees and expenses related to the 2023 Term Loan; and (v) financial guidance for 2023. It is uncertain whether any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do, what impact they will have on our results of operations and financial condition. Important risks and uncertainties that could cause our actual results and financial condition to differ materially from those indicated in forward-looking statements include, among others, changes in market or industry conditions, regulatory environment, competitive conditions, and receptivity to our services; changes in our strategy, future operations, prospects and plans; developments and uncertainties related to the Direct Contracting Entity program; our ability to realize expected financial results, including with respect to patient membership, total revenue and earnings; our ability to predict and control our medical cost ratio; our ability to grow market share in existing markets or enter into new markets and continue our growth; our ability to integrate our acquisitions and achieve desired synergies; our ability to maintain our relationships with health plans and other key payors; the impact of COVID-19 on our business and results of operations; our future capital requirements and sources and uses of cash, including funds to satisfy our liquidity needs; and our ability to recruit and retain qualified team members and independent physicians. The Company may also experience delays or difficulties in, and/or unexpected or less than anticipated results from (i) its efforts to achieve its vision by helping patients live their best lives, such as due to higher than expected medical costs or the spread of other pandemics; (ii) optimizing its operations, such as less than anticipated capacity utilization at its medical centers and/or less than anticipated growth in revenues, Adjusted EBITDA margins and/or cash flows, such as due to higher interest rates and/or a higher inflationary environment; (iii) its efforts to review all aspects of its business model to improve liquidity and cash flow, and maximize long-term shareholder value, such as due to tightness in the credit or M&A markets, higher interest rates, and/or a higher inflationary environment, which could adversely affect the Company's ability to improve its liquidity, cash flow and/or long-term shareholder value; (iv) using the proceeds from the 2023 Term Loan transaction for general corporate purposes, including repaying amounts outstanding under its existing revolving credit facility, and/or to pay related transaction fees, such as due to unanticipated demands on its available sources of cash; and/or (v) its efforts to achieve its financial guidance for 2023, such as due to a broad recessionary economic environment, less than anticipated utilization of its medical centers and/or access to less than anticipated sources of liquidity.
For a detailed discussion of the risks and uncertainties that could cause our actual results to differ materially from those expressed or implied by the forward-looking statements, please refer to our filings with the SEC. Factors other than those listed above could also cause the Company's results to differ materially from expected results. All information provided in this press release is as of the date hereof, and we undertake no duty to update or revise this information unless required by law.
Non-GAAP Financial Measures
This press release contains certain non-GAAP financial measures as defined by the SEC rules. EBITDA and Adjusted EBITDA have not been prepared in accordance with United States generally accepted accounting principles ("GAAP"). EBITDA is defined as net income (loss) before interest, income taxes, depreciation and amortization. Adjusted EBITDA is defined as EBITDA, adjusted to add back the effect of certain expenses, such as stock-based compensation expense, non-cash goodwill impairment loss, transaction costs (consisting of transaction costs and corporate development payroll costs), restructuring and other charges, fair value adjustments in contingent consideration, loss on extinguishment of debt and changes in fair value of warrant liabilities. For the periods through December 31, 2022, in calculating Adjusted EBITDA, the Company also excluded the impact of de novo losses consisting of costs associated with the ramp up of new medical centers and losses incurred for the 12 months after the opening of a new facility. The Company's management uses the non-GAAP financial measures as operating performance measures and as an integral part of its reporting and planning processes and to, among other things: (i) monitor and evaluate the performance of the Company's business operations, financial performance and overall liquidity; (ii) facilitate management's internal comparisons of the Company's historical operating performance of its business operations; (iii) facilitate management's external comparisons of the results of its overall business to the historical operating performance of other companies that may have different capital structures and debt levels; (iv) review and assess the operating performance of the Company's management team and, together with other operational objectives, as a measure in evaluating employee compensation, including bonuses and other incentive compensation; (v) analyze and evaluate financial and strategic planning decisions regarding future operating investments; and (vi) plan for and prepare future annual operating budgets and determine appropriate levels of operating investments. We believe these non-GAAP financial measures provide an additional tool for our management and investors to use in evaluating our financial condition, ongoing operating performance and trends and in comparing our financial measures with other similar companies. Management believes that the non-GAAP financial measures provide useful information to investors and greater transparency about the performance, from management's perspective, of the Company's overall business because such measures eliminate the effects of certain charges that are not directly attributable to the Company's underlying operating performance. Additionally, management believes that providing the non-GAAP financial measures enhances the comparability for investors in assessing the Company's financial reporting.
The non-GAAP financial measures should not be considered in isolation or as a substitute for their respective most directly comparable financial measures prepared in accordance with GAAP, such as net income/loss, operating income/loss, diluted earnings/loss per share or net cash provided by (used in) operating activities. The non-GAAP financial measures are subject to inherent limitations as they reflect the exercise of judgments by management about which expense, income and other items are excluded or included in determining these non-GAAP financial measures. In addition, other companies may define such non-GAAP measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of our non-GAAP financial measures as tools for comparison. The non-GAAP financial measures should be read in conjunction with the Company's financial statements and related footnotes filed with the SEC.
A reconciliation of those measures to their most directly comparable GAAP measures is available under the heading "Reconciliation of Non-GAAP Measures."
The Company has not provided a quantitative reconciliation of its forward-looking Adjusted EBITDA to GAAP net loss, its most directly comparable GAAP measure, because the Company cannot predict with a reasonable degree of certainty and without unreasonable efforts certain reconciling items, such as certain costs and expenses that are inherently uncertain and depend on various factors, some of which are outside of the Company's control. For these reasons, management is unable to assess the probable significance of the unavailable information, which could materially impact the computation of forward-looking GAAP net loss.
About Cano Health
Cano Health (NYSE: CANO) is a high-touch, technology-powered healthcare company delivering personalized, value-based primary care to approximately 310,000 members. With its headquarters in Miami, Florida, Cano Health is transforming healthcare by delivering primary care that measurably improves the health, wellness, and quality of life of its patients and the communities it serves. Founded in 2009, Cano Health has more than 4,000 employees, and operates primary care medical centers and supports affiliated providers in nine states and Puerto Rico. For more information, visit canohealth.com or investors.canohealth.com.
CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||
Three Months Ended December 31, | Years Ended December 31, | ||||||
(in thousands, except share and per share data) | 2022 | 2021 | 2022 | 2021 | |||
Revenue: | |||||||
Capitated revenue | $ 651,177 | $ 464,516 | $ 2,606,916 | $ 1,529,120 | |||
Fee-for-service and other revenue | 29,196 | 27,739 | 132,000 | 80,249 | |||
Total revenue | 680,373 | 492,255 | 2,738,916 | 1,609,369 | |||
Operating expenses: | |||||||
Third-party medical costs | 495,695 | 362,870 | 2,062,356 | 1,231,047 | |||
Direct patient expense | 77,677 | 59,141 | 254,867 | 179,353 | |||
Selling, general and administrative expenses | 107,827 | 93,347 | 422,443 | 252,133 | |||
Depreciation and amortization expense | 26,421 | 18,695 | 90,640 | 49,441 | |||
Transaction costs and other | 7,819 | 7,988 | 27,435 | 44,262 | |||
Change in fair value of contingent consideration | 4,500 | (7,528) | (5,025) | (11,680) | |||
Goodwill impairment loss | 323,000 | — | 323,000 | — | |||
Total operating expenses | 1,042,939 | 534,513 | 3,175,716 | 1,744,556 | |||
Income (loss) from operations | (362,566) | (42,258) | (436,800) | (135,187) | |||
Other income and expense: | |||||||
Interest expense | (19,627) | (14,928) | (62,495) | (51,291) | |||
Interest income | 7 | — | 14 | 4 | |||
Loss on extinguishment of debt | — | 110 | (1,428) | (13,115) | |||
Change in fair value of warrant liabilities | 81,155 | 58,349 | 72,771 | 82,914 | |||
Other income (expense) | 822 | 6 | 1,706 | (48) | |||
Total other income (expense) | 62,357 | 43,537 | 10,568 | 18,464 | |||
Net income (loss) before income tax expense | (300,209) | 1,279 | (426,232) | (116,723) | |||
Income tax expense (benefit) | 1,516 | 776 | 2,157 | 14 | |||
Net income (loss) | $ (301,725) | $ 503 | $ (428,389) | $ (116,737) | |||
Net income (loss) attributable to non-controlling interests | (153,356) | (158) | (221,117) | (98,717) | |||
Net income (loss) attributable to Class A c | $ (148,369) | $ 661 | $ (207,272) | $ (18,020) | |||
Net income (loss) per share attributable to Class | $ (0.61) | $ (0.12) | $ (0.95) | $ (0.11) | |||
Net income (loss) per share attributable to Class | $ (0.61) | $ (0.12) | $ (0.95) | $ (0.28) | |||
Weighted-average shares used in computation | |||||||
Basic | 242,187,512 | 177,649,657 | 219,166,852 | 170,507,194 | |||
Diluted | 242,187,512 | 177,649,657 | 219,166,852 | 475,697,225 | |||
CONSOLIDATED BALANCE SHEETS | ||||
As of, | ||||
(in thousands) | December 31, | December 31, | ||
Assets | ||||
Current assets: | ||||
Cash, cash equivalents and restricted cash | $ 27,329 | $ 163,170 | ||
Accounts receivable, net of unpaid service provider costs | 233,816 | 133,433 | ||
Prepaid expenses and other current assets | 79,603 | 20,632 | ||
Total current assets | 340,748 | 317,235 | ||
Property and equipment, net | 131,325 | 85,261 | ||
Operating lease right of use assets | 177,892 | 132,173 | ||
Goodwill | 480,375 | 769,667 | ||
Payor relationships, net | 567,704 | 576,648 | ||
Other intangibles, net | 226,059 | 248,973 | ||
Other assets | 4,824 | 13,582 | ||
Total assets | $ 1,928,927 | $ 2,143,539 | ||
Liabilities and stockholders' equity | ||||
Current liabilities: | ||||
Accounts payable and accrued expenses | $ 105,733 | $ 80,829 | ||
Current portion of notes payable | 6,444 | 6,493 | ||
Current portion of finance lease liabilities | 1,686 | 1,295 | ||
Current portion of contingent consideration | — | 3,123 | ||
Current portions due to sellers | 46,016 | 17,357 | ||
Current portion operating lease liabilities | 24,068 | 15,275 | ||
Other current liabilities | 24,491 | 36,664 | ||
Total current liabilities | 208,438 | 161,036 | ||
Notes payable, net of current portion and debt issuance costs | 997,806 | 915,266 | ||
Long term portion of operating lease liabilities | 166,347 | 122,935 | ||
Warrants liabilities | 7,373 | 80,144 | ||
Long term portion of finance lease liabilities | 3,364 | 2,181 | ||
Due to sellers, net of current portion | 15,714 | — | ||
Contingent consideration | 2,800 | 35,300 | ||
Other liabilities | 32,810 | 28,109 | ||
Total liabilities | 1,434,652 | 1,344,971 | ||
Stockholders' Equity | ||||
Shares of Class A common stock | 22 | 18 | ||
Shares of Class B common stock | 27 | 30 | ||
Additional paid-in capital | 540,989 | 397,443 | ||
Accumulated deficit | (286,032) | (78,760) | ||
Total Stockholders' Equity before non-controlling interests | 255,006 | 318,731 | ||
Non-controlling interests | 239,269 | 479,837 | ||
Total Stockholders' Equity | 494,275 | 798,568 | ||
Total Liabilities and Stockholders' Equity | $ 1,928,927 | $ 2,143,539 | ||
CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||
Years Ended December 31, | ||||
(in thousands) | 2022 | 2021 | ||
Cash Flows from Operating Activities: | ||||
Net loss | $ (428,389) | $ (116,737) | ||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||
Depreciation and amortization expense | 90,640 | 49,441 | ||
Change in fair value of contingent consideration | (5,025) | (11,680) | ||
Change in fair value of warrant liabilities | (72,771) | (82,914) | ||
Goodwill impairment loss | 323,000 | — | ||
Loss on extinguishment of debt | 1,428 | 13,115 | ||
Amortization of debt issuance costs | 3,826 | 4,887 | ||
Non-cash lease expense | 6,528 | 664 | ||
Class A shares issued for bonus award | 2,879 | — | ||
Stock-based compensation | 54,778 | 27,983 | ||
Changes in operating assets and liabilities: | ||||
Accounts receivable, net | (106,743) | (15,135) | ||
Other assets | 10,053 | (16,594) | ||
Prepaid expenses and other current assets | (51,662) | (11,779) | ||
Interest accrued due to seller | 100 | 1,464 | ||
Accounts payable and accrued expenses | 32,612 | 33,723 | ||
Other liabilities | (7,591) | 5,529 | ||
Net cash (used in) provided by operating activities | (146,337) | (118,033) | ||
Cash Flows from Investing Activities: | ||||
Purchase of property and equipment | (49,529) | (34,354) | ||
Acquisitions of subsidiaries including non-compete intangibles, net of cash acquired | (5,796) | (1,070,307) | ||
Payments to sellers | (8,830) | (26,587) | ||
Net cash (used in) provided by investing activities | (64,155) | (1,131,248) | ||
Cash Flows from Financing Activities: | ||||
Business Combination and PIPE financing | — | 935,362 | ||
Payments of long-term debt | (6,444) | (657,917) | ||
Debt issuance costs | (88) | (17,394) | ||
Proceeds from long-term debt | — | 1,120,000 | ||
Proceeds from revolving line of credit | 109,000 | — | ||
Repayments of revolving line of credit | (25,000) | — | ||
Proceeds from insurance financing arrangements | 2,529 | 1,701 | ||
Payments of principal on insurance financing arrangements | (2,529) | (1,701) | ||
Principal payments under finance leases | (1,429) | (1,227) | ||
Repayment of equipment loans | (510) | (314) | ||
Employee stock purchase plan withholding tax payments | (878) | — | ||
Other | — | 134 | ||
Net cash (used in) provided by financing activities | 74,651 | 1,378,644 | ||
Net increase (decrease) in cash, cash equivalents and restricted cash | (135,841) | 129,363 | ||
Cash, cash equivalents and restricted cash at beginning of year | 163,170 | 33,807 | ||
Cash, cash equivalents and restricted cash at end of period | $ 27,329 | $ 163,170 | ||
Reconciliation of Non-GAAP | |||||||
Three Months Ended December 31, | Years Ended December 31, | ||||||
(in thousands) | 2022 | 2021 | 2022 | 2021 | |||
Net income (loss) | $ (301,725) | $ 503 | $ (428,389) | $ (116,737) | |||
Interest income | (7) | — | (14) | (4) | |||
Interest expense | 19,627 | 14,928 | 62,495 | 51,291 | |||
Income tax expense (benefit) | 1,516 | 776 | 2,157 | 14 | |||
Depreciation and amortization expense | 26,421 | 18,695 | 90,640 | 49,441 | |||
EBITDA | $ (254,168) | $ 34,902 | $ (273,111) | $ (15,995) | |||
Stock-based compensation | 12,137 | 14,853 | 54,778 | 27,983 | |||
Goodwill impairment loss | 323,000 | — | 323,000 | — | |||
De novo (1) | 19,421 | 16,001 | 78,989 | 40,562 | |||
Transaction costs (2) | 10,500 | 9,006 | 34,449 | 48,303 | |||
Restructuring and other (3) | 1,426 | 2,370 | 10,769 | 7,883 | |||
Change in fair value of contingent | 4,500 | (7,528) | (5,025) | (11,680) | |||
Loss on extinguishment of debt | — | (110) | 1,428 | 13,115 | |||
Change in fair value of warrant liabilities | (81,155) | (58,349) | (72,771) | (82,914) | |||
Adjusted EBITDA | $ 35,661 | $ 11,145 | $ 152,506 | $ 27,257 | |||
____________________________ |
(1) De novo losses include those costs associated with the ramp up of new medical centers and losses incurred for the 12 months after the opening of a new facility. These costs collectively are higher than comparable expenses incurred once such a facility has been opened and is generating revenue, and would not have been incurred unless a new facility was being opened. The Company plans to reduce de novo investments in 2023 and accordingly, for future periods is modifying its definition of Adjusted EBITDA beginning January 1, 2023, to no longer exclude de novo losses in calculating Adjusted EBITDA. Using the newly-modified definition, Adjusted EBITDA would have been |
(2) Transaction costs included |
(3) Restructuring and other included |
Reconciliation of Full Year Non-GAAP | |||||
Years Ended December 31, | |||||
(in thousands) | 2022 | 2021 | 2020 | ||
Net loss | $ (428,389) | $ (116,737) | $ (71,064) | ||
Interest income | (14) | (4) | (320) | ||
Interest expense | 62,495 | 51,291 | 34,002 | ||
Income tax expense (benefit) | 2,157 | 14 | 651 | ||
Depreciation and amortization expense | 90,640 | 49,441 | 18,499 | ||
EBITDA | $ (273,111) | $ (15,995) | $ (18,232) | ||
Stock-based compensation | 54,778 | 27,983 | 528 | ||
Goodwill impairment loss | 323,000 | — | — | ||
Transaction costs | 34,449 | 48,303 | 43,333 | ||
Restructuring and other | 10,769 | 7,883 | 2,435 | ||
Change in fair value of contingent consideration | (5,025) | (11,680) | 65 | ||
Loss on extinguishment of debt | 1,428 | 13,115 | 23,277 | ||
Change in fair value of embedded derivatives | — | — | 12,764 | ||
Change in fair value of warrant liabilities | (72,771) | (82,914) | — | ||
Adjusted EBITDA (1) | $ 73,517 | $ (13,305) | $ 64,170 | ||
_______________________________ |
(1) The Company plans to reduce de novo investments in 2023 and accordingly, is modifying its definition of Adjusted EBITDA beginning January 1, 2023. The Company presents Adjusted EBITDA to adjust EBITDA to exclude the effect of certain gains/losses, such as non-cash stock-based compensation expense, non-cash goodwill impairment loss, and certain other non-operating items that are not directly attributable to the Company's underlying operating performance (the "Non-Operating Items"), such as acquisition, integration and divestiture transaction costs (including corporate development payroll costs), restructuring and other charges, fair value adjustments in contingent consideration, loss on the early extinguishment of debt, changes in fair value of warrant liabilities, results and gains/losses on discontinued operations and other miscellaneous expenses. The Company presents Adjusted EBITDA because the Company's management believes that some of these items may not occur in certain periods, the amounts recognized can vary significantly from period to period and these items do not facilitate an understanding of the Company's operating performance. |
Key Metrics | ||||||
Three Months Ended | ||||||
2022 | 2021 | % Change | ||||
Members: | ||||||
Medicare Advantage | 140,353 | 118,348 | 18.6 % | |||
Medicare DCE | 39,183 | 7,651 | 412.1 % | |||
Total Medicare | 179,536 | 125,999 | 42.5 % | |||
Medicaid | 76,717 | 66,500 | 15.4 % | |||
ACA | 53,337 | 34,506 | 54.6 % | |||
Total members | 309,590 | 227,005 | 36.4 % | |||
Member months: | ||||||
Medicare Advantage | 400,661 | 346,967 | 15.5 % | |||
Medicare DCE | 118,236 | 23,068 | 412.6 % | |||
Total Medicare | 518,897 | 370,035 | 40.2 % | |||
Medicaid | 229,104 | 196,754 | 16.4 % | |||
ACA | 159,178 | 90,715 | 75.5 % | |||
Total member months | 907,179 | 657,504 | 38.0 % | |||
Per Member Per Month ("PMPM"): | ||||||
Medicare Advantage | $ 1,084 | $ 1,098 | (1.3) % | |||
Medicare DCE | $ 1,374 | $ 1,261 | 9.0 % | |||
Total Medicare | $ 1,150 | $ 1,108 | 3.8 % | |||
Medicaid | $ 213 | $ 258 | (17.4) % | |||
ACA | $ 36 | $ 43 | (16.3) % | |||
Total PMPM | $ 718 | $ 706 | 1.7 % | |||
Medical centers | 172 | 130 | ||||
Key Metrics | ||||||
Twelve Months Ended | ||||||
2022 | 2021 | % Change | ||||
Members: | ||||||
Medicare Advantage | 140,353 | 118,348 | 18.6 % | |||
Medicare DCE | 39,183 | 7,651 | 412.1 % | |||
Total Medicare | 179,536 | 125,999 | 42.5 % | |||
Medicaid | 76,717 | 66,500 | 15.4 % | |||
ACA | 53,337 | 34,506 | 54.6 % | |||
Total members | 309,590 | 227,005 | 36.4 % | |||
Member months: | ||||||
Medicare Advantage | 1,503,286 | 1,167,848 | 28.7 % | |||
Medicare DCE | 485,562 | 69,707 | 596.6 % | |||
Total Medicare | 1,988,848 | 1,237,555 | 60.7 % | |||
Medicaid | 856,738 | 518,335 | 65.3 % | |||
ACA | 570,316 | 286,005 | 99.4 % | |||
Total member months | 3,415,902 | 2,041,895 | 67.3 % | |||
Per Member Per Month ("PMPM"): | ||||||
Medicare Advantage | $ 1,161 | $ 1,066 | 8.9 % | |||
Medicare DCE | $ 1,333 | $ 1,276 | 4.5 % | |||
Total Medicare | $ 1,203 | $ 1,078 | 11.6 % | |||
Medicaid | $ 221 | $ 355 | (37.7) % | |||
ACA | $ 45 | $ 39 | 15.4 % | |||
Total PMPM | $ 763 | $ 749 | 1.9 % | |||
Medical centers | 172 | 130 | ||||
View original content to download multimedia:https://www.prnewswire.com/news-releases/cano-health-announces-financial-results-for-the-fourth-quarter-and-full-year-2022-301760103.html
SOURCE Cano Health, Inc.
FAQ
What were Cano Health's total revenues for Q4 2022?
What was Cano Health's net loss for the full year 2022?
What is Cano Health's guidance for total revenue in 2023?
How many members did Cano Health have at the end of 2022?
What is the adjusted EBITDA guidance for Cano Health in 2023?
